Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapy and targeted oncology treatments and creating accessible, effective and potentially more affordable options for patients everywhere.
We are dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing and co-development opportunities that align with our areas of expertise, offering better patient outcomes and delivering significant value to the future of healthcare.
In addition to a research pipeline including several investigational medicines, Checkpoint Therapeutics has received U.S. Food and Drug Administration (FDA) approval for UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. For more information, visit www.unloxcyt.com.